Teladoc Health Inc. (TDOC) experienced a 5% plummet in its stock price during Friday's pre-market session, adding to the substantial decline it witnessed a day earlier following the release of a scathing short-seller report from Blue Orca Capital.
The report alleged that Teladoc misled investors about its BetterHelp platform, claiming that the company used AI-generated responses in place of licensed therapists without proper disclosures. Additionally, the report accused Teladoc of inflating profitability by shifting research and development expenses.
These allegations have raised concerns among investors about Teladoc's financial reporting and business practices, overshadowing the company's recent acquisition of Catapult Health for $65 million to expand its preventive healthcare offerings. Analysts have also released mixed projections for Teladoc's upcoming quarterly earnings report, with estimates ranging from a 23.5% year-over-year decline in earnings per share to modest revenue growth in certain segments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。